Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has secured a critical professorship in vaccinology for the future following a gift of £3.33 million from the Saïd family. The gift will enable Professor Sarah Gilbert, the inaugural post holder, to continue her ground-breaking research in the field, while also helping to ensure that Oxford remains at the forefront of vaccine development for generations to come.

Professor Sarah Gilbert at the Jenner Institute © University of Oxford / John Cairns

Professor Gilbert has 25 years of experience in the development of vaccines against malaria, influenza and emerging and re-emerging viral pathogens, including Lassa, Nipah and Middle East Respiratory Syndrome (MERS). In 2018 she began preparing for “Disease X”, the World Health Organisation’s term for a hypothetical, unknown pathogen that could cause a future epidemic. This preparation proved essential when, in January 2020, reports from China alerted the world to a new viral threat.

The genetic sequence of SARS-CoV-2 was released on 11 January and later that same day, Professor Gilbert and her team began designing Oxford’s COVID-19 vaccine: ChAdOx1 nCoV-19. Underpinned by Professor Gilbert’s research into vaccines that work by inducing strong and protective T cell responses, ChAdOx1 nCoV-19 became the first COVID-19 vaccine to enter into Phase III clinical trials. Professor Gilbert is currently working with the Oxford Vaccine Group, teams within the Jenner Institute and a network of international collaborators to test its efficacy in over 20,000 trial participants around the world.

The full story is available on the University of Oxford's Development Office website

Similar stories

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.